Study identification

PURI

https://redirect.ema.europa.eu/resource/43452

EU PAS number

EUPAS36180

Study ID

43452

Official title and acronym

Opioid drug utilization and comparative safety: a population-based cohort study

DARWIN EU® study

No

Study countries

Spain

Study description

This study aims to: 1.to describe the drug utilization (socio-demographic, clinical features, type, dosage, indication at the time of opioid therapy initiation) of the different opioids as well as to study the persistence of these drugs among subjects aged ≥ 18 years old in Catalonia, Spain, 2. to assess and compare the risk of pre-specified adverse events first between incident users of opioids and then compared to non-opioids pain-killers, 3. to study the association between long-term use of opioids compared to paracetamol. Methods: population-based cohort study (www.SIDIAP.org). Inclusion criteria: all new users of study drugs (no use in previous year) between 2007-2016, ≥18 years old and with ≥1 year of valid data. Follow-up: (latest of) start of the study period, 1-year of valid data until (earliest of) end of enrolment, discontinuation, date of last capturing data or event of interest. Outcomes: 1. opioids and non-opioid (NSAIDs, Cox-2 inhibitors, paracetamol, metamizole, aspirin) exposure. Variables: Socio-demographic, BMI, Charlson comorbidity index (CCI), frailty, cognitive and quality of life indexes, opioid use (type/dosage), prescriber and indication, 2. cardiovascular events (myocardial ischemia, stroke, heart failure and arrhythmia), fractures, falls, sleep and gastro-intestinal disorders, opioid dependence/abuse, all-cause mortality. Confounders: socio-demographic and socioeconomic status (MEDEA), medical conditions, CCI, surgeries and drugs (hypnotics, benzodiazepines, SSRI, anticonvulsant), number of different ATCs prescribed, GP visits, hospital admissions, falls and traffic accidents. Statistics: Kaplan Meier plots for drug persistence. Propensity score analysis and Cox regression model to estimate the relative risk according to drug use.

Study status

Planned
Research institution and networks

Institutions

Contact details

Carlen Reyes

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Data collection

Planned:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

IDIAP jordi Gol foundation
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable